IMUNOHISTOKEMIJSKA RAZINA HIF-1α U KARCINOMIMA ENDOMETRIJA VISOKOGA I NISKOGA GRADUSA by Schmid, Leon Romeo
   
UNIVERSITY OF SPLIT 
SCHOOL OF MEDICINE 
 
 
 
 
Leon Schmid 
 
 
 
 
EXPRESSION OF HYPOXIA-INDUCIBLE FACTOR-1 ALPHA 
 (HIF-1α) IN HIGH GRADE AND LOW GRADE ENDOMETRIAL 
CARCINOMAS 
 
 
 
Diploma thesis 
 
 
 
 
Academic year: 
 2016/2017 
 
 
Mentor:  
Sandra Zekic Tomas, MD,PhD 
 
 
 
Split, July 2017 
   
UNIVERSITY OF SPLIT 
SCHOOL OF MEDICINE 
 
 
 
 
Leon Schmid 
 
 
 
 
EXPRESSION OF HYPOXIA-INDUCIBLE FACTOR-1 ALPHA 
 (HIF-1α) IN HIGH GRADE AND LOW GRADE ENDOMETRIAL 
CARCINOMAS 
 
 
 
Diploma thesis 
 
 
 
 
Academic year: 
 2016/2017 
 
 
Mentor:  
Sandra Zekic Tomas, MD,PhD 
 
 
 
Split, July 2017 
Acknowledgments
I would like to express my gratitude towards the Mentor of my thesis, Sandra Zekic-Tomas
MD, PhD for her continuing support of our work and all the time she has invested into it.
Also I would like to thank the many other Professors, teaching and non-teaching staff of
University of Split, School of Medicine that enabled me to follow my dream to pursue a carrier as a
Doctor of Medicine
Last, but not least my sincerest thanks to my family, my father Manfred Schmid and my
mother Lana Schmid without their tireless support and devotion I could have never reached the
point where I am now.
Table of content
1. INTRODUCTION............................................................................................................................1
1.1. Epidemiology of endometrial carcinoma......................................................................................2
1.2. Etiology of endometrial carcinoma...........................................................................................2
1.3. Risk factors for endometrial carcinomas..................................................................................3
1.4. Pathology of endometrial carcinoma........................................................................................3
1.4.1. Gross morphology of endometrial carcinoma...................................................................3
1.4.2. Histology of endometrial carcinomas...............................................................................4
1.4.2.1. Endometrioid carcinoma...........................................................................................4
1.4.2.2. Mucinous carcinoma.................................................................................................6
1.4.2.3. Serous carcinomas.....................................................................................................6
1.4.2.4. Clear cell carcinoma..................................................................................................7
1.4.2.5. Undifferentiated carcinoma.......................................................................................7
1.5. Hypoxia-inducible factor 1 alpha.............................................................................................7
1.5.1. HIF-1α in endometrial carcinomas...................................................................................9
2. OBJECTIVES.................................................................................................................................10
3. MATERIAL AND METHODS......................................................................................................12
3.1.1. Material ...............................................................................................................................13
3.1.2. Immunohistochemical analysis ...........................................................................................13
3.1.3. Statistical analysis................................................................................................................15
4. RESULTS.......................................................................................................................................16
5. DISCUSSION.................................................................................................................................19
6. CONCLUSION..............................................................................................................................22
7. REFERENCES...............................................................................................................................24
8. SUMMARY....................................................................................................................................27
9. CROATIAN SUMMARY..............................................................................................................29
10. CURRICULUM VITAE...............................................................................................................31
1. INTRODUCTION
1
1.1. Epidemiology of endometrial carcinoma
Endometrial carcinoma is the second most common malignancy of the female reproductive
system after cancer of the uterine cervix (1). There were 320.000 newly diagnosed cases worldwide
in 2012, with an estimated 60.050 new cases to be diagnosed in 2017 in the USA and 10.470
estimated fatalities. It is the sixth most common cancer in women overall. Women of white race are
at highest risk, while incidence is lowest in Asian women (2).
The lifetime risk for women developing endometrial carcinoma is approximately 2-3% and
unlike many other cancers the number of new cases is still increasing (3, 4). The majority (75%), of
endometrial carcinomas develop in post-menopausal women with an average age of 60 years at the
time of diagnosis (5).
1.2. Etiology of endometrial carcinoma
Bokhman classified endometrial carcinomas in type I and type II tumors based on clinical,
metabolic and endocrine characteristics of the carcinoma (6).  Although that clasiffication was made
almost 35 years ago it is still valid in greater extent. The frequency of type I vs. type II carcinomas
is 70% to 30% respectively. 
Type  I  endometrial  carcinoma occur  most  often  in  obese/hyperlipidemic  women  and  is
associated with hyperestrogenism. They tend to be diagnosed in lower stages of the disease and
have a less aggressive clinical course, with rare metastasis at the time of diagnosis and usually less
than 50% depth of invasion in the uterine wall compared to type II tumors. Therefore, they carry a
more  favorable  prognosis  and  higher  survival  rates  (7).  Histologically,  type  I  endometrial
carcinomas are endometrioid adenocarcinomas and less often mucinous carcinomas. It was noted,
that endometriod carcinomas often exhibit a loss of  PTEN  gene. This is a negative regulator of
PI3K/AKT/mTOR pathways, whose uncontrolled stimulation leads to neocarcinogenesis. The same
was observed in  endometrial  hyperplasia.  It  is  postulated that  this  loss of function may play a
pivotal  role  in  the  pathogenesis  of  endometrioid  carcinomas  and  therefore  type  I  endometrial
carcinomas (8,  9). Furthermore,  it  is  believed  that  precursor  lesion  for  development  of  type  I
endometrial carcinoma is endometrial intraepithelial neoplasia (EIN) (10).
Type II endometrial carcinomas are less common than type I carcinomas and are usually less
differentiated. They have a more severe clinical course, with deeper invasion of the uterine wall,
more frequent metastasis and diagnosis often made in more advanced stages than type I tumors
(1,11).  Those tumors tend to be associated with atrophic endometrium, arise in non-obese women
and  are  independent  of  metabolic  or  endocrine  disturbances.  Furthermore,  they  have  different
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molecular  characteristics,  such  as  HER2 amplification  and  TP53 mutations.  TP53 is  a  tumor
suppressor gene, the product of which conserves stability in the human genome. Mutations of TP53
are present in up to 90% of serous carcinomas. HER2 is an oncogene and a member of the human
epidermal  growth  factor  receptor  family  (12).  Type  II  endometrial  carcinomas  comprises  the
following  histological  subtypes:  serous  carcinoma,  clear-cell  carcinoma,  undifferentiated
carcinoma. Mixed carcinomas are also included in the type II carcinoma group if they include one
of the components from those listed above. 
1.3. Risk factors for endometrial carcinomas
Several risk factors are implied in the development of endometrial carcinoma, most notably
those are: nulliparity, exposure to high levels of circulating estrogens, high age, breast cancer and its
associated intake of Tamoxifen, obesity, early menarche and late menopause. The minority of 10%
of endometrial carcinomas are hereditary (13).
One of the genetic conditions associated with endometrial  cancer is Lynch syndrome.
This  is  an  autosomal  dominant  genetic  disorder,  also  known  as  hereditary  non-polyposis
colorectal cancer (HNPCC), which is caused by germline transmission of defective mismatch
repair genes MSH1/6, MLH1 and PMS2. It is most known for it's tendency to cause colorectal
carcinoma, but it also causes endometrial carcinoma in 40-60% of cases. Endometrial carcinoma
caused by Lynch syndrome accounts especially for those cases that present before menopause,
which is the less frequent subtypes of patients (3,14). 
Another genetic syndrome that can cause endometrial carcinoma is Cowden syndrome. It is
also an autosomal dominant disorder, caused by a germline mutation of PTEN. The lifetime risk of
patients with Cowden syndrome to develop endometrial carcinoma is 28% and it's median age of
diagnosis  is  in the forties  (14).  Smoking,  use of birth control pills  and intrauterine devices are
protective factors.  Smoking can induce weight  loss and early menopause,  likewise it  alters the
body's metabolism of estrogen, thus is thought to reduce incidence of endometrial carcinoma (15).
1.4. Pathology of endometrial carcinoma
1.4.1. Gross morphology of endometrial carcinoma
Type  I  endometrial  carcinomas  arise  as  localized  polypoid  masses  or  as  a  diffusely
infiltrative tumor involving endometrial surface (Figure 1). The tumor usually spreads by direct
myometrial  invasion  and  can  encompass  adnexal  structures,  broad  ligament  or  eventually  can
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involve urinary bladder or colon. Regional lymph node involvement occurs in late stages of the
disease (16).
Figure 1. Gross appearance of endometrial carcinoma type I, presented as a large polypoid tumor 
with myometrial invasion in great extent. (Image taken from the archive of Pathology Department, 
Clinical Hospital Centre Split). 
Type II endometrial carcinomas arise in small atrophic uterus and often present as large 
bulky tumors or they show deep myometrial invasion. Likewise, in the time of diagnosis they are 
usually at more advance stage than type I endometrial carcinomas, with vascular invasion and 
lymph node involvement (16).
1.4.2. Histology of endometrial carcinomas
1.4.2.1. Endometrioid carcinoma
Endometrioid  carcinoma  is  also  known  as  estrogen-dependent  endometrial  carcinoma.
Histologically endometrioid carcinoma has a glandular or villoglandular architecture. It is lined by
columnar epithelium,  which  forms  smoothly contoured glandular  lumina  (Figure 2).  Neoplastic
cell's cytoplasm is eosinophilic and granular with mild to moderate nuclear atypia, except in poorly
differentiated forms (14).
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Contrary  to  well-differentiated  endometrial  carcinomas,  the  poorly  differentiated  forms
show  stromal  invasion,  altered  endometrial  stroma  or  papillary  architecture.  Endometrioid
carcinomas are often accompanied by atypical endometrial hyperplasia. 
Endometrioid carcinomas are histologically graded from grade 1 to grade 3, based on their
proportion of solid growth. Grade 1 has less than 5%, grade 2 between 6 and 50% and grade 3 more
than  50% of  solid  growth.  Endometrioid  carcinomas  grade  1  and  2  are  considered  low grade
carcinomas, while endometrioid carcinomas grade 3 are considered high grade carcinomas (14).
The most common forms of differentiation in endometrioid carcinomas show squamous and
secretory differentiation patterns. Squamous type of differentiation is the most common, with 10-
25%, while the latter comprises only about 2%. Even less common patterns of differentiation are
villoglandular, sertoli-form and microglandular types (14).
FIGO stage  and  grade  of  the  tumor,  age,  histological  grade,  myometrial  and lymphatic
invasion  are  predictive  for  the  course  of  the  disease  and  apply  to  all  variants  of  endometrial
carcinoma.  Notably  outer-half  myometrial  invasion  is  associated  with  significant  decrease  in
survival (14).
Figure 2.  Microscopic image of well  differentiated endometrioid endometrial  carcinoma (H&E,
magnification 100x; Olympus BX41) (image taken by candidate at the Pathology Department). 
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1.4.2.2. Mucinous carcinoma
When  an  endometrial  carcinoma  comprises  more  than  50%  of  mucinous  cells,  it  is
considered a mucinous carcinoma. Clinically, mucinous carcinomas behave similarly to the more
common endometrioid carcinoma, however they are almost always well differentiated and have a
relatively  good  prognosis.  Histologically  mucinous  carcinomas  are  (villo)glandular,  lined  by
uniform mucinous cells with little stratification. They often shows squamous differentiation, mild to
moderate nuclear atypia and low mitotic activity. Typically myometrial invasion is limited to the
inner-half  of  myometrium  (14).  Mucinous  carcinomas  are  considered  low  grade  endometrial
carcinomas (14). 
1.4.2.3. Serous carcinomas
Serous carcinoma exhibits a papillary and/or a glandular architecture with diffuse, marked
nuclear  pleomorphism  (Figure  3). Serous  carcinomas  are  typical  type  II  tumors.  Histologically
speaking, they are always considered as high grade endometrial carcinomas. Serous carcinomas,
confined to the endometrium have an overall good prognosis, while those that have reached extra-
uterine spread almost always end with the death of the patient (14).
Figure 3. Histology of serous endometrial carcinoma (H&E, magnification 100x; Olympus BX41)
(image taken by candidate at the Pathology Department). 
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1.4.2.4. Clear cell carcinoma
Clear  cell  carcinomas  are  made  up  of  polygonal  or  hobnail-shaped  cells  with  clear  or
eosinophilic cytoplasm and often high grade nuclear atypia. They are uncommon and comprise only
about 2% of endometrial carcinomas. They are also categorized as type II endometrial carcinoma
and high grade carcinomas, have a mean age of diagnosis in the late sixties, and the most common
presenting symptom is also post-menopausal bleeding. The overall survival varies between 21-75%,
with an assumed 50% mean 5-year survival reported by most studies (14).
1.4.2.5. Undifferentiated carcinoma
Undifferentiated carcinoma arising in the endometrium is considered a rare neoplasm with
only a few studies published thus far. This limited number of studies is most likely a reflection of
the under-recognition of this tumor because of a lack of diagnostic criteria to separate it from poorly
differentiated endometrial carcinomas (17).
1.5. Hypoxia-inducible factor 1α
Hypoxia-inducible factor 1α (HIF-1α) is encoded by the HIF1 gene and plays an essential
role in the adaptive cellular response to hypoxia. HIF-1 is a transcription factor and consists of an α
and  a  β-subunit,  which  together  form  a  heterodimer  and  undergo  conformational  changes  in
response to variations of oxygen levels (18). 
HIF-1 expression is regulated by enzymatic hydroxylation of conserved proline residues that
causes  the  degradation  under  normoxia  via  the  ubiquitin  E3  ligase  complex. There  are  two
pathways involved in the expression of HIF-1 : synthesis of it’s α -subunit functions via an oxygen
dependent pathway and increases with falling oxygen levels. Contrary to that, the expression of the
β-subunit is oxygen independent (18). 
HIF-1α  is  expressed  in  relatively  low  quantities  in  cells  in  normoxic  conditions,  but
markedly  increases  in  hypoxic  cellular  environments,  one  can  therefore  conclude,  that  HIF-1α
induces transcription of genes,  which increase oxygen delivery to hypoxic tissues, increase cell
survival  and  proliferation  in  hypoxia,  and  alter  glucose  and  iron  metabolism  (19). HIF-1α  is
responsible for the increased production of insulin-like growth factor-2 (IGF2) and transforming
growth factor-α  (TGF-α).  This  also  promotes  cell  survival  and proliferation. Furthermore,  it  is
implicated in the glucose metabolism. HIF-1α regulates expressions of all enzymes in the glycolytic
pathway, as well as expression of the glucose transporters GLUT1 and GLUT3, which mediate
cellular glucose uptake (18). Hypoxia was found to increase the expression of transferrin, probably
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to enhance the iron transport to erythroid tissues. The transferrin receptor is a hypoxia-inducible
HIF-1α target gene, enabling cellular transferrin uptake. Another HIF-1α target for iron metabolism
is ceruloplasmin, which is needed to oxidise ferrous to ferric ion. Ferric ion is the form that can be
bound by transferrin. Hypoxic ceruloplasmin induction is likely to support iron supply to erythroid
tissue (18).
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1.5.1. HIF-1α in endometrial carcinomas
HIF-1α is implicated in several aspects of tumor growth: It activates the transcription of
various genes, like those responsible for the production of VEGF and erythropoietin. In that way it
promotes  oxygen delivery to  hypoxic tissue by neoangiogenesis  and increased  erythropoesis  in
hypoxic  conditions.  Overexpression  of  HIF-1α  was  noted  in  tumors  from  various  anatomical
locations such as cervical squamous cell carcinomas, head and neck cancers, soft tissue tumors and
colon cancer (20, 21). Overexpression of HIF-1α has also been noted in endometrial carcinomas.
Sivridis et al studied HIF-1α expression in type I endometrial carcinoma  only and found it to be
overexpressed (22). Pansare et al found the HIF-1α expression to be higher in type II carcinomas
compared to type I carcinomas (23). To the best of my knowledge, none of the studies investigated
HIF-1α immunohistochemical expression in endometrial carcinomas based on histological grading
into low grade and high grade endometrial carcinomas and compared them. 
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2. OBJECTIVES
10
 
The aim of this research was to investigate the immunohistochemical expression of HIF-1α
in low grade and high grade endometrial carcinomas and to compare them. Since hypoxia is a key
factor in cell survival in circumstances of uncontrolled growth, which carcinomas represent, we
hypothesize that  the expression of  HIF-1α is  going to be greater  in  endometrial  carcinomas of
higher grade compared to the lower graded cases. Likewise, we hypothesize that high grade tumors
are going to be larger, with deeper myometrial invasion and more frequent vascular invasion and
lymph node involvement. 
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3. MATERIAL AND METHODS
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3.1.1. Material 
Our study included 10 cases of high grade endometrial carcinoma and 10 cases of low grade
endometrial carcinoma. All  of the samples included in the study were obtained from Pathology
Department  archive.  They  included  surgical  material  that  was  sent  for  gross  and  histology
assessment at the Pathology Department, University Hospital Split in the period from January 2015
till January 2017. Grading of endometrial carcinoma was done based on their histologic appearance
according  to  WHO  2014  (14).  Low  grade  group  of  endometrial  carcinomas  included  well
differentiated endometrioid carcinomas (histological grade 1), while high grade carcinomas were
serous carcinomas and endometrioid carcinomas of histological grade 3. The age of the patients at
the time of diagnosis was obtained from the pathology report. From the pathology report additional
data  were noted:  depth of myometrial  invasion,  presence of  vascular  invasion and lymph node
involvement. 
3.1.2. Immunohistochemical analysis 
Immunohistochemistry was performed on one tumor representative section for each sample
as  follows:  paraffin  sections  were  mounted  on super  frost  slides  (Thermoscientific,  Darmstadt,
Germany) and processed in an autostainer (Ventana Bench Mark Ultra Autostainer, Ventana Roche,
Tucson, Arizona, USA). As primary antibody HIF-1α (rabbit polyclonal IgG antibody, clone H-206,
Santa Cruz Biotechnology Inc.,  Dallas, Texas, USA) was used, followed by Ultra view Universal
DAB  detection  kit (Ventana,  Tucson,  Arizona,  USA)  (Figure  4&5). Brown  membranous  and
cytoplasmic  staining  was  considered  positive  and  sample  of  normal  colonic mucosa  served  as
positive  control.  The  immunohistochemical  expression  of  HIF-1α  was  assessed  with  Olympus
BX41 microscope (Olympus, Tokyo, Japan) using semi-quantitative HSCORE method.  HSCORE
was calculated by the following formula: HSCORE=∑Pi (i+1), were “I” is the staining intensity
marked with 1, 2 or 3 (weak (+), moderate (++), or strong (+++), and Pi is the percentage of cells of
each staining category in the total cell count (24).
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Figure  4.  Imunohistochemical  expression  of  HIF-1α  in  low-grade  endometrial  carcinoma
(magnification 100x, Olympus BX41) (image taken by candidate at the Pathology Department).
Figure  5.  Imunohistochemical  expression  of  HIF-1α  in  high-grade  endometrial  carcinoma
(magnification 100x, Olympus BX41) (image taken by candidate at the Pathology Department). 
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3.1.3. Statistical analysis
MedCalc  software  (MedCalc  software,  Mariakerke,  Belgium)  was  used  for  statistical
analysis  of  the  data.  Following  statistical  tests  were  performed:  χ2-test,  t-test  for  independent
samples and Mann-Whitney test, depending on the result distribution. Statistical significance was
set at p < 0.05. Results were expressed as mean with standard deviation or median with minimum
and maximum value, depending on the result distribution determined by Kolmogorov-Smirnov test.
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4. RESULTS
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Our study included 10 cases of high grade endometrial carcinoma and 10 cases of low grade
endometrial carcinomas based on the histological grading according to WHO 2014 (14). All of the
cases were diagnosed after gross and microscopic examination on operative material at Pathology
Department, Clinical Hospital Center Split in the period from January 2015 till January 2017. 
In high grade endometrial carcinoma group there were 5 cases of serous carcinomas and the
same number of endometrioid carcinomas of histological grade 3, while in low grade group all of
the adenocarcinomas were of endometrioid type histological grade 1. 
The following results are presented in Table 1. Immunohistochemical expression of HIF-1α
was higher in high grade endometrial carcinomas compered to low grade endometrial carcinomas,
however  that  difference  wasn’t  statistically significant  (z=0.541,  P=0.589).  Carcinomas  in  high
grade group were significantly larger compared to the ones in low grade group (t=2.572, DF=18,
P=0.019). At the time of diagnosis 9 patients from high grade group had lymphadenectomy and in 3
cases (30%) lymph node involvement was recorded, compared to 3 lymphadenectomies in low
grade group, all of them without lymph node involvement (χ2=8.5, DF=2, P=0.014). There was no
statistically significant difference in the depth of myometrium invasion and presence of vascular
invasion between studied groups (t=1.273, DF =18, P=0.219) (χ2=1.879, DF=1, P=0.170).
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Table  1.  Immunohistochemical  expression  of  HIF-1α,  tumor  size,  depth  of  myometrium
invasion, presence of vascular invasion and lymph node involvement in high grade (HG) and
low grade (LG) endometrial carcinomas
HG endometrial 
carcinomas
N=10
LG endometrial 
carcinomas
N=10
P
HIF-1 alpha
(HSCORE)
3.9 (3.1-4) 3.75 (2.1-4) 0.589*
Tumor size (cm) 4.95 ± 1.36 2.95 ± 1.23 0.019†
Depth of myometrium invasion
(cm)
1.2 ± 0.77 0.75 ± 0.81 0.219†
Presence of vascular invasion 5 (50%) 2 (20%) 0.170††
Presence  of  lymph  node
involvement
3 (30%) 0 0.014††
*Mann-Whitney test; †Student t-test; ††Chi-squared test 
Values are presented as arithmetic mean ± standard deviation, median with minimum and maximum
value and as general numbers
At the time of diagnosis average age of patient with high grade endometrial carcinoma was
66.9 ± 9.81 years compared to 65.8 ± 8.03 years in low grade endometrial carcinoma group. The
age difference wasn’t statistically significant (t=0.274, DF= 18, P=0.787).
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5. DISCUSSION
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The availability  of  oxygen is  a  necessity  for  survival  of  all  human cells,  unaltered  and
malignant ones alike. HIF-1α helps cells to adapt to hypoxia in various ways. Deduced from the fact
of the fast  growth of many carcinomas,  it  seems obvious that  tumor cells  possess mechanisms
which  enable  them not  only  to  multiply  faster,  but  also  to  tolerate  hypoxia  better  than  non-
malignant cells. High graded carcinomas often grow faster than an organism manages to provide
adequate nutrition and oxygenation through e.g. neoangeonesis, hypoxia is a common environment
for individual cells. This is met with, beside other coping mechanisms, increased production of
HIF-1α resulting in upregulation of VEGF and increased blood supply to tumor cells, which fastens
their  dissemination  and  results  in  higher  malignancy.  Tumor  hypoxia  through  activation  of
angiogenesis  helps  in  tumor  progression  and  metastasis  and  makes  solid  tumors  resistant  to
radiation and chemotherapy (23).  All of the facts listed above negatively affects the outcome of
treated cancer patients. Studies of the cervical squamous cell carcinomas have shown that low-pO2
tumors exhibited larger tumor extensions and more frequent (occult) parametrial spread, as well as
lymph-vascular space involvement, compared to well-oxygenated tumors of similar clinical stage
and size (20).
We postulated that immunohistochemical expression of HIF-1α will be higher in high grade
carcinomas, since histological grade correlates well with tumor aggressive behavior and therefore
indirectly with the amount of hypoxia the tumor creates. Indeed, our results showed higher HIF-1α
expression in high grade carcinomas compared to low grade carcinomas. However this difference
was not statistically significant (z=0.541, P=0.589). We believe the main reason for this statistical
insignificance lies in the number of the studied samples, which we consider the main limitation of
our study. In a study similar to ours, by Pansare et al which had bigger sample size, a statistically
significant higher expression of HIF-1α was found in type II endometrial carcinomas compared to
type I carcinomas (23). The mentioned study observed 108 cases of type I and 48 cases of type II
carcinomas. Unlike our study where we made distinct difference between high grade and low grade
carcinomas based on histology, their study included 19 cases of high grade carcinomas (histological
grade 3 according to WHO) in type I carcinomas.
However,  both  of  our  findings  suggest  HIF-1α's  function  as  an  important  anti-hypoxia
adaptation mechanism of carcinomatous cells. Furthermore, it potentially identifies it as a target for
future therapy strategies. Development and successful  clinical results of the anti-VEGF Antibody
Bevacizumab, which inhibits neoangiogenesis, thereby decreasing blood supply of tumor cells and
reducing their  available oxygen and nutrients, proves the effectiveness of the concept of taking
advantage of the altered characteristics of malignant compared to healthy tissue in oncology.
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A similar concept could be envisioned targeting HIF-1α. If cellular tolerance for hypoxia
could be lowered, either by decreasing or stopping HIF-1α's expression, or by blocking it's action,
this  might  become  another  milestone  in  our  repertoire  of  cancer  treatment,  which  is  yet
underutilized. Several efforts have been made to exploit this, but so far none led to the development
of a certified clinical drug with that mechanism of action (25). Further investigation and research in
this matter should therefore be encouraged. 
Our study also found that high grade carcinoma are significantly larger in size with higher
frequency of lymph node involvement at the time of diagnosis compared to low grade carcinomas.
Likewise, vascular invasion was more common in high grade carcinomas and myometrial invasion
was  greater  compared  to  low  grade  carcinomas.  These  findings  are  consistent  with  previous
knowledge on clinical behavior and morphological characteristic of endometrial carcinomas (14).  
21
6. CONCLUSION
22
1. Our study has shown, that endometrial  carcinomas of high grade are significantly larger
compared to their lower graded counterparts and have a higher frequency of lymph node
involvement.
2. Immunohistochemical expression of HIF-1α is greater in high grade endometrial carcinomas
compared to low grade carcinomas, however that difference wasn’t statistically significant.
We  assume  the  missing  statistical  significance  to  be  founded  in  the  small  sample  size
examined. Further investigation regarding this matter should be performed.
3. HIF-1a could be an exploitable target in yet to be developed pharmacologic treatment of
endometrial carcinomas and possibly other malignancies as well.
23
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8. SUMMARY
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Objectives: to investigate  HIF-1α  immunohistochemical expression in high grade and low grade
endometrial carcinomas and to compared the results. Patient’s age at the time of diagnosis, tumor
size, depth of myometrial invasion, presence of vascular invasion and lymph node involvement was
also noted for each studied group and compared. 
Subject and method: 10 cases of high grade endometrial carcinoma and 10 cases of low grade
endometrial carcinoma were enrolled in the study. Histological grading of endometrial carcinomas
was done according to WHO 2014. Immunohistochemistry with primary antibody HIF 1α was used.
For  the  assessment  of  HIF1α immunohistochemical  expression  HSCORE method  was  applied.
Patient’s  age  at  the  time  of  diagnosis,  tumor  size,  depth  of  myometrial  invasion,  presence  of
vascular invasion and lymph node involvement were noted from pathology reports. 
Results: Our  results  showed  higher  HIF-1α  immunohistochemical  expression  in  high  grade
carcinomas  compared  to  low  grade  carcinomas,  however  this  difference  wasn’t  statistically
significant. High grade carcinomas had statistically significantly larger tumors and more frequently
involved lymph nodes. Likewise high grade tumors had deeper myometrial invasion, more frequent
vascular invasion and older patients at the time of diagnosis then low grade carcinomas, however
these differences weren’t statistically significant. 
Conclusion: Our study has shown the higher immunohistochemical expression of HIF-1α in high
grade endometrial carcinomas compared to low grade carcinomas, however that difference wasn’t
significant.
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9. CROATIAN SUMMARY
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Ciljevi: odrediti  imunohistokemijsku razinu  HIF1α u karcinomima endometrija  (EK) visokog i
niskog gradusa te dobivene rezultate međusobno usporediti.  Nadalje,  dodatni cilj  bio je utvrditi
postoji  li  razlika  u  dobi  pacijentica  u  vrijeme  postavljajenja  dijagnoze,  veličini  tumora,  dubini
invazije  miometrija,  prisutnosti  vaskularne  invazije  i  zahvaćenosti  limfnih  čvorova  između
ispitivanih skupina.
 
Ispitanici i  metode: 10 uzoraka EK visokog gradusa i  isti  broj  uzoraka EK niskog gradusa je
uključen  u  studiju.  Gradus  tumora  je  određen  prema  WHO  kriterijima  iz  2014.  godine.  Za
imunohistokemijsku analizu korišteno je primarno protutijelo HIF1α, imunohistokemijska razina
istog  procijenjena  je  uporabom HSCORE metode.  Podatci  o  dobi  pacijentica,  veličini  tumora,
dubini  invazije  miometrija,  prisutnosti  vaskularne  invazije  i  zahvaćenosti  limfnih  čvorova
zabilježeni su iz patolohistoloških nalaza.  
Rezultati: Imunohistokemijska razina HIF1α je bila veća u skupini EK visokoga gradusa u odnosu
na skupinu EK niskoga  gradusa,  ali  taj  rezultat  nije bio statistički značajan.  Tumori iz  skupine
visokoga gradusa su bili značajno veći i imali su učestaliju zahvaćenost limfnih čvorova u odnosu
na EK niskoga gradusa. Pacijentice s EK visokoga gradusa su bile starije u odnosu na pacijentice s
EK niskoga gradusa, imale su veću učestalost vaskularne invazije i dublju invaziju miometrija ali
navedeni rezultati nisu bili statistički značajni. 
Zaključak: Rezultati ove studije su pokazli veću imunohistokemijsku razinu HIF1α u EK visokoga
gradusa u odnosu na EK niskoga gradusa ali bez statističke značajnosti, najvjerojatnije zbog male
veličine uzorka, stoga je potrebno ponoviti studiju na većem broju uzoraka. 
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